2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Opioids, Women’s Health, Adverse Events, Biological Processes, Hematopoiesis, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Immunodeficiency, Infectious Diseases, Bacterial, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4692 The association of pain, silent cerebral infarcts and neurocognition in adults with SCD: The PAIN+SCAN study

Jennifer Asiamah Afranie-Sakyi, MD, Melissa Davis, MD, MBA2, Modupe Karimi, BA3, Joanna Cole, DNP, FNP-BC4, Ashlei Moore, BSN, RN5, Layla N. Van Doren, MD, MBA6, Cecelia Calhoun, MD, MPHS, MBA7
1 Yale School of Medicine, New Haven, Connecticut, United States
2 Yale School of Medicine, New Haven, Connecticut, United States
3 Yale University, New Haven, Connecticut, United States
4 Yale New Haven Health, New Haven, Connecticut, United States
5 Yale New Haven Health, New Haven, Connecticut, United States
6 University of California San Francisco, San Francisco, California, United States
7 Yale School of Medicine, New Haven, Connecticut, United States

Adults with sickle cell disease (SCD) are at risk for acute and chronic pain and cerebrovascular disease (stroke, silent cerebral infarcts (SCI), and cognitive impairment).  SCI, defined as a lesion at least 3mm in 1 dimension visible in at least 2 planes of T2-weighted magnetic resonance imaging (MRI) without an associated neurological deficit, can progress to overt strokes and are associated with cognition. Literature suggests SCI prevalence is 39% by age 18 and 53% by age 30. SCI and cognition screening in adults is low (PMID: 42263745), thus the true prevalence is unclear. This prospective observational study examines the association between pain, SCI, and cognition in adults with SCD.

Adults ≥18 years with SCD of any genotype were recruited at a single center SCD program from December 2024 to present. Those on chronic red cell transfusions, prior stroke, epilepsy, cerebral vasculopathy, or known neurocognitive disorder were excluded. All participants completed 1) the NIH Toolbox for Cognition Battery to evaluate multiple domains of fluid (capacity for new knowledge) and crystallized (prior verbal knowledge) cognition 2) multiplanar 3T MR imaging and angiogram (MRA) to assess for SCI-like lesions and vasculopathy 3) 14-day pain diary, and 4) Patient Reported Outcomes Measurement System (PROMIS) forms on pain intensity, interference, nociceptive and neuropathic pain. Number of pain crises in the last 12 months was obtained by self-report and medical record. MR images were reviewed by a board-certified neuroradiologist. Cognitive impairment was defined as age-adjusted composite scores 1 standard deviation (SD) below the standardized mean of 100±15. Tests of correlation and regression were performed.

We present this interim analysis of the first 39 adults to complete the PAIN+ SCAN study as of June 2026. Median (IQR) age 35 years (27-40); males made up 53.8%. The cohort was 41% HbSC genotype and 33.3% HbSS. The median of self-reported pain crises in the past 12 months was 5 (2 -15), median hospitalizations was 2 (1-5). Median number of days with pain in 14-day period was 11 (6 -14).  A PROMIS pain T-score of 50 is the general population norm. Median neuropathic pain was 45.8 (37.2 - 53.9), nociceptive pain 47.7 (39.4 -53.5), pain interference 61.1 (54.8 - 64.5), and pain intensity 60.3 (48 - 67.8). SCI-like lesions were identified in 46.2% of adults. The number of lesions ranged from 1 to >80 with sizes from 2-3mm to 8mm. 5 adults had abnormal MRA including one newfound Moya-Moya.

Median (range) total cognition score was 89 (52-134) with 38.46% 1 SD below the mean representing impairment range.  Median fluid composite score was 86 (61-133) with 48.72% 1 SD below, and median crystalized composite was 99 (49 -146) with 23.08% 1 SD below. Total cognition score was moderately negatively correlated to number of days with pain (r = -0.40), pain interference (r = -0.43), intensity (r = -0.46), nociceptive (r= -0.40) and neuropathic pain (r= -0.50) (each p <0.05) and fluid composite was similar (r= -0.35 – -0.42, each p<0.05). Crystallized composite was negatively correlated with neuropathic pain only (r= -0.35, p <0.05).  Number of pain crises in the past 12 months was not significantly correlated with cognition. In a multivariate linear regression, increased pain interference (β= -0.926, p= 0.009) and pain intensity (β= -0.744, p= 0.009) were significant predictors for lower cognition score. Age, sex, hydroxyurea, genotype were not significant predictors. Those with SCI-like lesions were more likely to have total cognition score in the impairment range (55.5% v 23.8% χ2= 4.127 p=0.042). In a logistic regression model, pain interference (OR=1.14, p= 0.048) was a significant predictor of SCI. Hydroxyurea use was associated with lower odds of SCI (OR=0.14, p=0.046).  

In this interim prospective analysis, patient-reported chronic pain, but not acute pain crises, was a predictor of lower cognition; SCI-like lesions were associated with pain interference and lower cognition. This suggests a correlation between cerebrovascular disease and chronic pain.  Discovery of new-found SCI-like lesions and other abnormalities in our cohort showcases a higher prevalence of cerebrovascular disease than previously estimated at our center. Larger prospective studies are essential to define the relationship between pain, SCI, and cognition and to develop multi-modal approaches that improve quality of life for adults with SCD.  

 

Jennifer Asiamah Afranie-Sakyi, MD: No relevant conflicts of interest to declare.